BioSpaceOriginal article
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
Phase 2positiveCarmot assetPositive
AI Analysis
Summary
Roche's Carmot asset achieved positive Phase 2 results in diabetes, normalizing blood sugar and reducing weight. This readout represents a key catalyst in Roche's metabolic pipeline, which includes assets from its $2.7 billion acquisition of Carmot Therapeutics and partnership with Zealand Pharma.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
normalized blood sugar and reduced weight
Importance:7/10
Sentiment:
0.70
Phase 2 datametabolic diseasediabetesweight lossblood sugar controlacquisition assetRocheZealand Pharma
Read the original article
Published by BioSpace on September 22, 2026 1:31 PM